

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 July 2023 (13.07.2023)



(10) International Publication Number
WO 2023/133510 A1

(51) International Patent Classification:

A61B 5/00 (2006.01) A61B 5/0245 (2006.01)
A61B 5/318 (2021.01) A61B 5/361 (2021.01)
A61B 5/024 (2006.01)

(21) International Application Number:

PCT/US2023/060238

(22) International Filing Date:

06 January 2023 (06.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/297,426	07 January 2022 (07.01.2022)	US
63/334,852	26 April 2022 (26.04.2022)	US
17/978,835	01 November 2022 (01.11.2022)	US

(71) Applicant: **XYRA, LLC** [US/US]; 120 Hatona Drive, Santa Rosa, California 95403 (US).

(72) Inventors: **DRUZGALA, Pascal**; c/o Xyra, LLC, 120 Hatona Drive, Santa Rosa, California 95403 (US). **MILNER, Peter Gerard**; c/o Xyra, LLC, 120 Hatona Drive, Santa Rosa, California 95403 (US).

(74) Agent: **MAJKUT, Stephanie** et al.; BANNER & WITCOFF, LTD., 1100 13th Street, N.W., Suite 1200, Washington, District of Columbia 20005-4051 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,

(54) Title: METHODS FOR REDUCING THE RISK OF STROKES BY PHARMACOTHERAPY TO REDUCE THE NUMBER AND DURATION OF ATRIAL FIBRILLATIONS

CLN-209 Clinical Development Plan
Long-term Open Label Dose Titration Study of Budiadarone
to Determine Safety and Efficacy




FIGURE 1

(57) Abstract: Disclosed are methods to treat patients with AFib by monitoring their heart rhythm to determine the presence and/or the number of episodes of long duration AFib, and optionally the extent of AFib burden. Patients who meet threshold requirements are qualified for the treatment of AFib with a dosage of budiadarone. Patient monitoring is continued to confirm that the patient is and remains responsive to budiadarone therapy including dose adjusting the patient to achieve such therapy. Subsequently, monitoring is continued to confirm that the patient remains responsive. These methods allow for treatment of the AFib and, correspondingly, reduce or delay the risk of stroke and/or congestive heart failure in the treated patient.

[Continued on next page]

NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*